These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 16706977)

  • 21. Modification of interdomain interfaces within the A3C1C2 subunit of factor VIII affects its stability and activity.
    Wakabayashi H; Fay PJ
    Biochemistry; 2013 Jun; 52(22):3921-9. PubMed ID: 23659383
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hemophilia A mutations associated with 1-stage/2-stage activity discrepancy disrupt protein-protein interactions within the triplicated A domains of thrombin-activated factor VIIIa.
    Pipe SW; Saenko EL; Eickhorst AN; Kemball-Cook G; Kaufman RJ
    Blood; 2001 Feb; 97(3):685-91. PubMed ID: 11157485
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Contribution of A1 subunit residue Q316 in thrombin-activated factor VIII to A2 subunit dissociation.
    Parker ET; Lollar P
    Biochemistry; 2007 Aug; 46(34):9737-42. PubMed ID: 17676877
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Variable contributions of basic residues forming an APC exosite in the binding and inactivation of factor VIIIa.
    Takeyama M; Wintermute JM; Manithody C; Rezaie AR; Fay PJ
    Biochemistry; 2013 Apr; 52(13):2228-35. PubMed ID: 23480827
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Contribution of factor VIII light-chain residues 2007-2016 to an activated protein C-interactive site.
    Takeyama M; Wakabayashi H; Fay PJ
    Thromb Haemost; 2013 Feb; 109(2):187-98. PubMed ID: 23224054
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hemophilia A mutations within the factor VIII A2-A3 subunit interface destabilize factor VIIIa and cause one-stage/two-stage activity discrepancy.
    Hakeos WH; Miao H; Sirachainan N; Kemball-Cook G; Saenko EL; Kaufman RJ; Pipe SW
    Thromb Haemost; 2002 Nov; 88(5):781-7. PubMed ID: 12428094
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Structural investigation of zymogenic and activated forms of human blood coagulation factor VIII: a computational molecular dynamics study.
    Venkateswarlu D
    BMC Struct Biol; 2010 Feb; 10():7. PubMed ID: 20184747
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mild hemophilia A caused by increased rate of factor VIII A2 subunit dissociation: evidence for nonproteolytic inactivation of factor VIIIa in vivo.
    Pipe SW; Eickhorst AN; McKinley SH; Saenko EL; Kaufman RJ
    Blood; 1999 Jan; 93(1):176-83. PubMed ID: 9864159
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A1 subunit-mediated regulation of thrombin-activated factor VIII A2 subunit dissociation.
    Parker ET; Doering CB; Lollar P
    J Biol Chem; 2006 May; 281(20):13922-30. PubMed ID: 16513639
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cathepsin G, a leukocyte protease, activates coagulation factor VIII.
    Gale AJ; Rozenshteyn D
    Thromb Haemost; 2008 Jan; 99(1):44-51. PubMed ID: 18217133
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A3 domain residue Glu1829 contributes to A2 subunit retention in factor VIIIa.
    Wakabayashi H; Zhou Q; Varfaj F; Fay PJ
    J Thromb Haemost; 2007 May; 5(5):996-1001. PubMed ID: 17371488
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Coagulant properties of hybrid human/porcine factor VIII molecules.
    Lollar P; Parker ET; Fay PJ
    J Biol Chem; 1992 Nov; 267(33):23652-7. PubMed ID: 1429706
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Activated factor X cleaves factor VIII at arginine 562, limiting its cofactor efficiency.
    Plantier JL; Rolli V; Ducasse C; Dargaud Y; Enjolras N; Boukerche H; Négrier C
    J Thromb Haemost; 2010 Feb; 8(2):286-93. PubMed ID: 19874476
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Activation, activity and inactivation of factor VIII in factor VIII products.
    Orfeo T; Elsman R; Gissel M; Mann KG; Butenas S
    Haemophilia; 2016 May; 22(3):462-73. PubMed ID: 26822998
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Heme binds to factor VIII and inhibits its interaction with activated factor IX.
    Repessé Y; Dimitrov JD; Peyron I; Farrokhi Moshai E; Kiger L; Dasgupta S; Delignat S; Marden MC; Kaveri SV; Lacroix-Desmazes S
    J Thromb Haemost; 2012 Jun; 10(6):1062-71. PubMed ID: 22471307
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Functional characteristics of N8, a new recombinant FVIII.
    Christiansen ML; Balling KW; Persson E; Hilden I; Bagger-Sørensen A; Sørensen BB; Viuff D; Segel S; Klausen NK; Ezban M; Lethagen S; Steenstrup TD; Kjalke M
    Haemophilia; 2010 Nov; 16(6):878-87. PubMed ID: 20546031
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of activation of the coagulation factor VIII in interaction with vWf, phospholipid, and functioning within the factor Xase complex.
    Saenko EL; Shima M; Sarafanov AG
    Trends Cardiovasc Med; 1999 Oct; 9(7):185-92. PubMed ID: 10881749
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Binding studies of the enzyme (factor IXa) with the cofactor (factor VIIIa) in the assembly of factor-X activating complex on the activated platelet surface.
    Ahmad SS; London FS; Walsh PN
    J Thromb Haemost; 2003 Nov; 1(11):2348-55. PubMed ID: 14629468
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Factor VIII mutated with Lys1813Ala within the factor IXa-binding region enhances intrinsic coagulation potential.
    Nakajima Y; Takeyama M; Oda A; Shimonishi N; Nogami K
    Blood Adv; 2023 Apr; 7(8):1436-1445. PubMed ID: 36322904
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Increasing hydrophobicity or disulfide bridging at the factor VIII A1 and C2 domain interface enhances procofactor stability.
    Wakabayashi H; Griffiths AE; Fay PJ
    J Biol Chem; 2011 Jul; 286(29):25748-55. PubMed ID: 21628455
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.